An evidence-based review of natalizumab therapy in the management of Crohn’s disease

References

• LichtensteinGHanauerSSandbornWManagement of Crohn’s disease in adultsAm J Gastroenterol200910.1038/ajg2008.168
   PubMed Web of Science ®Google Scholar
• FeaganBGVreelandMGLarsonLRAnnual cost of care for Crohn’s disease: a payor perspectiveAm J Gastroenterol2000951955196010950042
   PubMed Web of Science ®Google Scholar
• BodgerKCost of illness of Crohn’s diseasePharmacoeconomics20022063965212162753
   PubMed Web of Science ®Google Scholar
• BaumgartDCSandbornWJInflammatory bowel disease:clinical aspects and establishing and evolving therapiesLancet2007121641165717499606
   PubMed Web of Science ®Google Scholar
• SastangiJSilverbergMSVermeireSColombelJFThe Montreal Classification of inflammatory bowel disease:controversies, consensus and implicationsGut20065574975316698746
   PubMed Web of Science ®Google Scholar
• SandbornWJFazioVWFeaganBGAGA technical review on perianal Crohn’s diseaseGastroenterol200312515081530
   PubMed Web of Science ®Google Scholar
• ItzkowitzSHYioXInflammation and cancer IV. Colorectal cancer in inflammatory bowel disease:the role of inflammationAm J Physiol Gastrointest Liver Physiol2004287G71715194558
   PubMed Web of Science ®Google Scholar
• GillenCDWalmsleyRSPriorPUlcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitisGut199435159015927828978
   PubMed Web of Science ®Google Scholar
• LolyCBelaicheJLouisEPredictors of severe Crohn’s diseaseScand J Gastroenterol20084394895419086165
   PubMed Web of Science ®Google Scholar
• SutherlandLSingletonJSessionsJDouble blind, placebo controlled trial of metronidazole in Crohn’s diseaseGut199132107110751916494
   PubMed Web of Science ®Google Scholar
• HanauerSBTop-down vs step-up approaches in chronic inflammatory bowel disease:presumed innocent or presumed guiltyNat Clin Pract Gastroent Hepatol20052493
   PubMedGoogle Scholar
• LichtensteinGRYanSBalaMInfliximab maintenance treatment reduces hospitalizations, surgeries and procedures in fistulizing Crohn’s diseaseGastroenterol2005128862869
   PubMed Web of Science ®Google Scholar
• GisbertJPPanesJloss of response and requirement of infliximab dose intensification in Crohn’s disease: A reviewAm J Gastroenterol200910476076719174781
   PubMed Web of Science ®Google Scholar
• SchnitzlerFFidderHFerranteMLong term outcome of treatment with infliximab in 614 patients with Crohn’s disease:results from a single centre cohortGut20095849250018832518
   PubMed Web of Science ®Google Scholar
• SandbornWJRutgeertsPEnnsRAdalimumab induction therapy for Crohn’s disease previously treated with infliximabAnn Int Med200714682983817470824
   PubMed Web of Science ®Google Scholar
• LobbRRHelmerMEThe pathopysiologic role of alpha 4 integrins in vivoJ Clin Invest1994172217287525645
   PubMed Web of Science ®Google Scholar
• RutgeertsPVervermeireSVan AsscheGBiological therapies for inflammatory bowel diseasesGastroenterol200913611821197
   PubMed Web of Science ®Google Scholar
• MillerDHKhanQASheremataWAA controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med200353466472
   Google Scholar
• BestWRBecktlJMSingletonJWKernFDevelopment of a Crohn’s disease activity index. National Cooperative Crohn’s disease studyGastroenterol197670439444
   PubMed Web of Science ®Google Scholar
• TarganSRFeagenBGFedorakRNNatalizumab for the treatment of active Crohn’s disease: Results of the Encore trialGastroenterol200713216721683
   PubMed Web of Science ®Google Scholar
• SandbornWJColombelJFEnnsRNatalizumab induction and maintenance therapy for Crohn’s diseaseN Engl J Med20053531912192516267322
   PubMed Web of Science ®Google Scholar
• MacDonaldJKMcDonaldJWDNatalizumab for induction of remission in Crohn’s disease (review)Cochrane Database Syst Rev Rev2007CD006097
   Google Scholar
• HymasJSWilsonDCThomasANatalizumab therapy for moderate to severe Crohn’s disease in adolescentsJ Pediatr Gastroenterol Nutr20074418519117255829
   PubMed Web of Science ®Google Scholar
• LewisJDC-reactive protein: anti-placebo or predictor of responseGastroenterol200512911141116
   PubMed Web of Science ®Google Scholar
• SandsBEKozarekRSpainhourJSafety and tolerability of concurrent natalizumab treatment for patients with Crohn’s disease not in remission while receiving infliximabInflamm Bowel Dis20071321117206633
   PubMed Web of Science ®Google Scholar
• BrooksBRWalkerDLProgressive multifocal leukoencephalopathyNeurol Clin198422993136503939
   PubMed Web of Science ®Google Scholar
• BergerJRPallLLanskaDWhitemanMProgressive multifocal leukoencephalopathy in patients with HIV infectionJ Neurovirol1998459689531012
   PubMed Web of Science ®Google Scholar
• BergerJRKoralnikIProgressive multifocal leukoencephalopathy and natalizumab – unforeseen consequencesN Engl J Med353441441615947082
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DemastersBKTylerKLProgressive multifocal luekoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosisN Engl J Med200535336937415947079
   PubMed Web of Science ®Google Scholar
• AnnetteLGScottWAAriJGAndrewWBDanielPProgressive multifocal leukoencephalopathy in a patient treated with natalizumabN Eng J Med2005353375381
   PubMed Web of Science ®Google Scholar
• Van AsscheGVan RanstMSciotRProgressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s diseaseN Engl J Med200535336236815947080
   PubMed Web of Science ®Google Scholar
• YousryTAMajorEORyschkewitschCEvaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathyN Engl J Med200635492493316510746
   PubMed Web of Science ®Google Scholar
• VerbeeckJVan AsscheGRydingJViral loads in patients with Crohn’s disease treated with immunosuppression:can we screen for elevated risk of PMLGut2008571393139718436577
   PubMed Web of Science ®Google Scholar
• CliffordDBNatlaizumab and PML: A risky businessGut2008571347134918791114
   PubMed Web of Science ®Google Scholar
• McGuireDBarhiteSHollanderHJC virus DNA in cerebrospinal fluid of human immunodeficiency virus infected patients. Predictive value for progressive multifocal leukoencephalopathyAnn Neurol1995373953997695239
   PubMed Web of Science ®Google Scholar
• MarzocchettiADi GiambenedettoSCingolaniAReduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent anti retroviral therapyJ Clin Microbiol2005434175417716081969
   PubMed Web of Science ®Google Scholar
• HallCDDafniUSimpsonDFailure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infectionN Engl J Med1998338134513519571254
   PubMed Web of Science ®Google Scholar
• KhatriBFoxRKooAThe effect of plasma exchange in accelerating clearance of natalizumab in patients with multiple sclerosisResults of the PLEX study. [Poster] 23rd congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)Oct 11–14, 2007Prague
   Google Scholar
• The Tysabri TOUCH (package insert) prescribing programBiogen Idec and Elan pharmaceuticals www.tysabri.com
   Google Scholar
• What is the cost of Tysabri infusion? www.steadyhealth.com. Posted 05/31/2008
   Google Scholar
• FeaganBGGreenbergGRWildGTreatment of active Crohn’s disease with MLN0002, a humanized antibody to the alpha4 beta7 integrinClin Gastoenterol Hepatol2008613701371
   PubMed Web of Science ®Google Scholar